Tesamorelin and EGRIFTA: Approved Use vs. General Weight Loss
EGRIFTA WR contains tesamorelin and is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states that it is not indicated for weight-loss management.
By PacificRx editorial team · Published
At a glance
EGRIFTA WR contains tesamorelin and is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states that it is not indicated for weight-loss management. That specific indication should not be generalized to ordinary weight loss or every body-composition goal.
- An approved indication describes a specific clinical context.
- Abdominal-fat outcomes are not the same as general weight loss.
- A compounded preparation does not share an approved product's status.
On this page
What does the approved indication establish?
The EGRIFTA WR label describes a growth hormone-releasing factor analog for excess abdominal fat in adults with HIV-associated lipodystrophy. The population and condition are part of the indication; they should not disappear when the product is summarized in a marketing claim.
The label also includes limitations, including that the product is not indicated for weight-loss management. A phrase such as belly-fat treatment, without the clinical context, can therefore leave an inaccurate impression.
How should I compare claims?
Identify whether a claim concerns the approved product, a particular clinical study, an off-label proposal, or a compounded preparation. These are different contexts with different evidence and regulatory questions.
A finding involving a specific study population does not establish the same benefit for every adult seeking a body-composition change. Ask what outcome was measured and whether the evidence applies to your actual goal and circumstances.
What should a consultation clarify?
Discuss the exact product, clinical rationale, medical history, alternatives, potential harms, and monitoring. A clinician should explain both what is known and what remains uncertain for any proposed use.
Compounded tesamorelin is not an FDA-approved generic or automatically equivalent to an EGRIFTA product. Confirm which formulation's instructions govern the actual prescription instead of borrowing directions from an approved brand with a different presentation.